News
Latest findings on plasma cell biology, myeloma, and light-chain disease. Newest first.
AI model reads bone marrow smear morphology to predict cytogenetic risk group; AUC 0.76 to 0.85 across markers; plasmablastic features drive high-risk calls.
Case report: non-secretory myeloma presenting as plasma cell leukaemia, plasmablast morphology on smear. n = 1.
Retrospective cohort, 111 MM patients. Morphology heterogeneity correlates with Durie-Salmon and ISS stage; combined Vitamin D and IL-6 assessment proposed.
Reviews morphologic heterogeneity from mature to anaplastic; defines plasmablast threshold at 2% as adverse independent prognostic factor.
Comprehensive review of the IRF4-BLIMP1-XBP1 transcription factor hierarchy in B cell to plasma cell terminal differentiation and myeloma.
Reviews the division-linked epigenetic reprogramming that drives B cell commitment to the plasma cell fate; covers Blimp-1, XBP-1, and DNA hypomethylation.
Defines molecular signature of antibody-secreting cells; confirms stark transcriptional divide between B cells and plasma cells.
PERK branch of UPR suppressed at plasma cell differentiation; IRE1-XBP1 branch active; chaperones BiP, GRP94, ERdj3 induced for high-volume Ig synthesis.
A fraction of TG2-specific gut plasmocytes and patient mAbs ignore GDP-bound inactive TG2 but bind active TG2 with or without substrate.
SSR4 rises along the B cell to plasmacyte trajectory in colorectal cancer; deletion lowers antibody output and serum IgG1 and raises high-mannose Ig. Mouse and human tissue.
715 marrow samples. Automated CD138 selection succeeded in 86% vs 75% manual (p < 0.001). Plasmocyte infiltration of 3% or more gives an 80% probability of FISH success.